Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021
Allergy & Anaphylaxis Australia made a submission to to Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme (PBAC) listing of Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD).